Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2017-02-08

Clinical Trial Update: Treatment With hOKT3gamma1(Ala-Ala) in T1DM [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating hOKT3gamma1(Ala-Ala) for Type 1 diabetes mellitus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • hOKT3gamma1(Ala-Ala) (hOKT3gamma1(Ala-Ala))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: TERMINATED